Can MRI Biomarkers Predict Triple-Negative Breast Cancer?

被引:22
|
作者
Moffa, Giuliana [1 ]
Galati, Francesca [1 ]
Collalunga, Emmanuel [1 ]
Rizzo, Veronica [1 ]
Kripa, Endi [1 ]
D'Amati, Giulia [1 ]
Pediconi, Federica [1 ]
机构
[1] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, I-00161 Rome, Italy
关键词
triple-negative breast cancer; 3 T MRI; DWI; breast cancer prognostic factors; INTERNATIONAL EXPERT CONSENSUS; RESONANCE-IMAGING FEATURES; CONTRAST-ENHANCED MRI; MOLECULAR CLASSIFICATION; PRIMARY THERAPY; RECOMMENDATIONS; DESCRIPTORS; SUBTYPES; TUMORS;
D O I
10.3390/diagnostics10121090
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to investigate MRI features of triple-negative breast cancer (TNBC) compared with non-TNBC, to predict histopathological results. In the study, 26 patients with TNBC and 24 with non-TNBC who underwent multiparametric MRI of the breast on a 3 T magnet over a 10-months period were retrospectively recruited. MR imaging sets were evaluated by two experienced breast radiologists in consensus and classified according to the 2013 American College of Radiology (ACR) BI-RADS lexicon. The comparison between the two groups was performed using the Chi-square test and followed by logistic regression analyses. We found that 92% of tumors presented as mass enhancements (p = 0.192). 41.7% of TNBC and 86.4% of non-TNBC had irregular shape (p = 0.005); 58.3% of TNBC showed circumscribed margins, compared to 9.1% of non-TNBC masses (p = 0.001); 75% of TNBC and 9.1% of non-TNBC showed rim enhancement (p < 0.001). Intralesional necrosis was significantly associated with TNBC (p = 0.016). Rim enhancement and intralesional necrosis risulted to be positive predictors at univariate analysis (OR = 29.86, and 8.10, respectively) and the multivariate analysis confirmed that rim enhancement is independently associated with TNBC (OR = 33.08). The mean ADC values were significantly higher for TNBC (p = 0.011). In conclusion, TNBC is associated with specific MRI features that can be possible predictors of pathological results, with a consequent prognostic value.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [41] Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer
    Golden, Daniel I.
    Lipson, Jafi A.
    Telli, Melinda L.
    Ford, James M.
    Rubin, Daniel L.
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2013, 20 (06) : 1059 - 1066
  • [42] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [43] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [44] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [45] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [46] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436
  • [47] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    CANCER CONTROL, 2010, 17 (03) : 173 - 176
  • [48] Triple-negative breast cancer: an update
    Boolbol, Susan K.
    Cate, Sarah P.
    BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
  • [49] Morphotypes of the triple-negative breast cancer
    Koleckova, M.
    Kolar, Z.
    Ehrmann, J.
    Korinkova, G.
    Trojanec, R.
    VIRCHOWS ARCHIV, 2017, 471 : S296 - S296
  • [50] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600